Promoting Evidence-Based Prescribing, Pharmaceutical Innovation, and Access to Medicines


January 12, 2016 | from Modafinil for cognitive neuroenhancement in healthy non-sleep-deprived subjects: A systematic review A recent study published in the European Neuropsychopharmacology journal in November 2015 has found that Modafinil seems to be well tolerated by healthy individuals and exhibits enhancement of attention, executive functions, and learning. This study goes a long was to outline the discrepancies of todays literature focusing on Modafinil and specifically neuroenhancement. With larger ramification’s concerning the rising popularity of nootropics for “off-label” use by the general public from online pharmacied such as ModaPharma


  • February 11, 2012 | from FDA Press Release FDA issues draft guidance on biosimilar product development The U.S. Food and Drug Administration today issued three draft guidance documents on biosimilar product development to assist industry in developing such products in the United States.

  • February 11, 2012 | from FDA Press Release FDA issues draft guidance on biosimilar product development The U.S. Food and Drug Administration today issued three draft guidance documents on biosimilar product development to assist industry in developing such products in the United States.

February 11, 2012 | from A drug that has hit the USA market is known as Etizolam , which is legal for research use only, and is not authorized for medical use by the Food and Drug Administration. It does not fall under the Federal Analog Act, so its legal status falls into the same grey area that occurs with synthetic marijuana. In and of itself, it is not illegal thus far to possess Etizolam. However, according to Ashland County Criminal Justice Council Coordinator Terry Schemenauer, use of the substance as a recreational drug is illegal under both state and federal law.

AMSA Policy Change Campaign
AMSA Scorecard
Make Change at Your School
Contact the Steering Committee